Nitkin et al. (2022) further found that patients receiving anti‐VEGF therapy required pulmonary vasodilators more often than those treated with laser therapy, suggesting a possible link to pulmonary hypertension. Here, VEGFA is linked to pulmonary arterial hypertension.